Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism. 1984

R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist

Theophylline plasma clearance (Clp) and clearance to its metabolites ( Clm ), as well as antipyrine saliva clearance ( Clsal ) and its Clm were compared in a crossover study in 25 healthy subjects. They were selected with regard to smoking status (nine smokers, 16 nonsmokers) and oxidation phenotype of debrisoquine and sparteine (six poor metabolizers [PMs] and 19 extensive metabolizers [EMs]). Clm of theophylline (1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine) correlated (r greater than or equal to 0.92) to each other and to total theophylline Clp (r greater than or equal to 0.97). Smokers had higher Clm to all metabolites, particularly by the N-demethylation pathways. After correction for the effect of smoking, there was no difference between EMs and PMs with regard to theophylline Clp or Clm . Antipyrine clearances by EMs and PMs ( Clsal and Clm of 4-OH-antipyrine, 3-OH- methylantipyrine , or norantipyrine) also did not differ. Antipyrine Clsal and Clm correlated to theophylline Clp (r between 0.50 and 0.69). It is concluded that theophylline metabolism (N-demethylations and C-oxidation) is not under the same genetic control as sparteine and debrisoquine oxidations, and that there may be a partial overlap in factors that regulate the metabolism of theophylline and antipyrine.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone

Related Publications

R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
March 1983, British journal of clinical pharmacology,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
April 1993, British journal of clinical pharmacology,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
April 1980, Clinical pharmacology and therapeutics,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
October 1991, British journal of clinical pharmacology,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
November 1980, Life sciences,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
November 1989, British journal of clinical pharmacology,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
January 1990, Pharmacology & therapeutics,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
January 1990, Pharmacology & therapeutics,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
November 1995, Drug metabolism and disposition: the biological fate of chemicals,
R Dahlqvist, and L Bertilsson, and D J Birkett, and M Eichelbaum, and J Säwe, and F Sjöqvist
January 1991, British journal of clinical pharmacology,
Copied contents to your clipboard!